NovoCure Ltd
NVCR· Nasdaq
NVCRNovoCure Ltd
Source filing unavailable
| Metric | Q3 2015 | Q3 2014 |
|---|---|---|
| Revenue | $8.95M | $4.37M |
| Net Income | -$26.02M | -$18.32M |
| EPS Diluted | -$2.09 | -$1.45 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
NovoCure Ltd · CIK 1645113 · Engraved from SEC EDGAR
